Discovery of multiple isoforms of the p53 tumor suppressor protein

25 years after the initial discovery of p53, Dr. David Lane and colleagues at the University of Dundee have discovered multiple isoforms of the p53 tumor suppressor protein.

Their paper, which will be released online ahead of print in Genes & Development, establishes that, like the other p53 family members p63 and p73, p53 exists in human cells in at least six different isoforms. Dr. Lane and colleagues identified a heretofore unrecognized internal promoter and alternative splice exons in p53 mRNA.

While further research is needed to delineate how the various p53 isoforms affect p53 tumor suppressor activity, the scientists did establish that some p53 isoforms can modulate p53 transcriptional activity and p53-induced cell death. Interestingly, Prof. Lane and colleagues observed that p53 isoforms are abnormally expressed in breast tumors presenting no mutation of the p53 gene. David Lane and Jean-Christophe Bourdon, group leader in David Lane's laboratory, consider the discovery of p53 isoforms to be "a major breakthrough in the understanding of cancer formation.

The determination of p53 isoforms expression in human cancers will help to identify patients at risk of developing aggressive cancer and to define their drug sensitivity in order to treat the patient with the most efficient drug."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals tumor and immune cell interactions in craniopharyngiomas